

NHS England Evidence Review:

Human normal immunoglobulin for scleromyxedema NHS England URN: 2271



NHS England Evidence Review

Human normal immunoglobulin for scleromyxedema

Completed: May 2023

Prepared by NICE on behalf of NHS England Specialised Commissioning

Contents

1. Introduction	3
2. Executive summary of the review	4
3. Methodology	8
4. Summary of included studies	9
5. Results	11
6. Discussion	16
7. Conclusion	18
Appendix A PICO document	19
Appendix B Search strategy	24
Appendix C Evidence selection	26
Appendix D Excluded studies table	27
Appendix E Evidence table	28
Appendix F Quality appraisal checklists	33
Appendix G GRADE profiles	34
Glossary	39
References	40

1. Introduction

This evidence review examines the clinical effectiveness, safety, and cost effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care for treating people with scleromyxedema compared with current standard care without immunoglobulin.

Immunoglobulin is licensed for use in primary and secondary immunodeficiencies and immunomodulation in several conditions. Its use in scleromyxedema is off label (<u>Summary of product characteristics</u>).

In addition, the review scope included the identification of possible subgroups of patients within the included studies who might benefit from treatment with immunoglobulin more than others, as well as the route of administration, dosage, frequency, and duration of treatment.

2. Executive summary of the review

This evidence review examines the clinical effectiveness, safety, and cost effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care for treating people with scleromyxedema compared with current standard care without immunoglobulin. The searches for evidence published since February 2013 were conducted on 14 February 2023 and identified 90 references. The titles and abstracts were screened and 5 full text papers were obtained and assessed for relevance.

Four case series were included in the evidence review (Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020, and Rongioletti et al. 2013). Guarneri et al. 2017 was based in Italy and included 8 participants who had completed at least 6 cycles of IV immunoglobulin infusions within the first 6 months of planned treatment. Mahevas et al. 2020 was based in France and included 33 people (25 received IV immunoglobulin). Mecoli et al. 2020 was based in the USA and included 15 participants (12 people on maintenance IV immunoglobulin, and 3 people who had not previously received IV immunoglobulin). Rongioletti et al. 2013 was a multi-centre study based in Europe and included 30 people (11 received IV immunoglobulin without concomitant interventions within a treatment period). Standard care in the studies was heterogenous. Other treatments included, but were not limited to, cyclosporine, azathioprine, cyclophosphamide, methotrexate, and steroids and IV immunoglobulin was used from first to fifth line. None of the studies directly compared immunoglobulin to a control group (either placebo or active comparator).

In terms of clinical effectiveness:

- **Disease activity.** Four case series provided very low certainty evidence for the critical outcome of disease activity, one was designed to assess the acute response to IV immunoglobulin after 1 to 2 weeks (12 people on maintenance therapy [mean 4.2 years], 3 people treatment naïve), one with a mean follow up of 34 months, one with a mean follow up of 44 months, and one with a mean follow up of 4.3 years. The studies suggest that disease activity scores and the number of people who had complete or partial response improved compared with baseline in people with scleromyxedema treated with IV immunoglobulin.
- **Systemic involvement/extracutaneous manifestations.** One case series provided very low certainty evidence for the critical outcome of systemic involvement/extracutaneous manifestations after treatment with IV immunoglobulin. Systemic involvement and extracutaneous manifestations improved in 6/8 participants (mean follow up of 44 months).
- Health related quality of life. One case series provided very low certainty evidence for the critical outcome of health related quality of life. The health assessment questionnaire disability index (HAQ-DI) score reduced 1 to 2 weeks after treatment with IV immunoglobulin, but this was not statistically significant.
- Duration of clinical improvement or response to treatment. One case series provided very low certainty evidence for the important outcome of duration of clinical improvement or response to treatment. It showed that 6/8 participants needed maintenance infusions to maintain disease control (mean follow up of 44 months). The 2 participants who obtained complete response stopped treatment after 7 and 11 months but relapses occurred after 6 and 25 months, respectively. Reintroduction of IV immunoglobulin was successful in both cases.

- Withdrawal or reduction of other immunosuppressive treatments. No evidence was identified for the important outcome of withdrawal or reduction of other immunosuppressive treatments.
- Progression to dermatoneuro syndrome. Two case series provided very low certainty evidence for the important outcome of progression to dermatoneuro syndrome. In one case series, 2/8 participants progressed to dermatoneuro syndrome (mean follow up of 44 months) and, in another case series, 4/15 participants who had IV immunoglobulin first line (mean follow up 21 months) and 1/6 who had IV immunoglobulin second line (mean follow up 24 months) progressed to dermatoneuro syndrome.
- **Hospital admissions.** No evidence was identified for the important outcome of hospital admission.
- Survival. No evidence was identified for the important outcome of survival.

In terms of safety:

• Two case series provided very low certainty evidence for safety. In one case series, there were 13 adverse events in 5 people after treatment with IV immunoglobulin during a mean follow up of 44 months. In one case series, 1/15 people who had IV immunoglobulin first line had a serious side effect (mean follow up 21 months).

In terms of cost effectiveness:

• No evidence was identified for cost effectiveness.

In terms of subgroups:

 One case series provided evidence for response to treatment in people who were treatment naïve and in people on maintenance IV immunoglobulin. Response to treatment was greater in people who were treatment naïve compared with people who were on maintenance IV immunoglobulin. However, no conclusions can be drawn.

Limitations

The evidence review included 4 case series (Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020, and Rongioletti et al. 2013). It is difficult to conduct high quality studies in rare diseases such as scleromyxedema as there are few eligible participants and previous treatment regimens can differ substantially. All included studies have many limitations. For example, there were no comparators, Mahevas et al. 2020 and Rongioletti et al. 2013 were mainly retrospective, and the sample sizes were small (n=8, n=25, n=15, and n=11, respectively). All outcomes were considered to have very low certainty using modified GRADE.

No evidence was found comparing IV immunoglobulin with standard care. The studies were prospective and open label. Consequently, are subject to bias due to unblinding of participants and investigators, which can impact on patient reported outcomes or investigator assessed outcomes. Many of the reported outcomes could be considered subjective, including pain scores, Rodnan Skin Scores, and Physicians Global Assessment for disease severity (PGA), and are therefore subject to bias.

As with many small case series, the studies were not powered for statistical hypothesis testing and the data should be regarded as descriptive only. Case series are subject to bias, such as selection bias and observation bias, and confounding, and cannot prove that an intervention (such as IV immunoglobulin) caused a particular outcome, only that it is associated with that outcome.

In Mecoli et al. 2020, outcomes were reported 1 to 2 weeks after a single dose of IV immunoglobulin. Therefore, longer term outcomes, including complete or partial response, which are typically seen over several treatments, were not available for the 3 treatment naïve participants. Before treatment comparisons were also not available for the 12 participants on maintenance treatment. In Guarneri et al. 2017 (n=8), outcomes were reported at the last follow up assessment which ranged from 15 to 87 months. In this case series, 2/8 people achieved complete response and 6/8 people achieved partial response. In Mahevas et al. 2020, 10/15 people who had IV immunoglobulin first line achieved a complete response and 5/15 achieved a partial response. However, 2 of these people also experienced failure and 4 had dermatoneuro syndrome or died. Similarly for the people who had IV immunoglobulin second line 2/6 achieved complete response and 4/6 achieved partial response but one person experienced failure and one person had dermatoneuro syndrome or died. 'Failure' was not defined in the study and the definitions of response were subjective. In Rongioletti et al. 2013, 3/6 people who had IV immunoglobulin first line achieved complete response and 3/6 achieved partial response. The 5 people who had IV immunoglobulin second, third, or fifth line, all achieved partial response. Complete response was defined as disappearance of symptoms and no detectable findings on examination, however the outcome of partial response (decrease in skin changes and improvement in systemic symptoms) could be considered subjective.

The critical outcome of health related quality of life was only reported in the case series with a 1 to 2 week follow up (Mecoli et al. 2020). No significant difference was reported in the HAQ-DI. It is likely that a longer term follow up is needed to observe any differences.

Guarneri et al. 2017 reported adverse events over the mean 44 month follow up period. Five people experienced a total of 13 adverse events including asthenia, headache, exfoliative keratolysis, acute hypertensive episodes, fever, dizziness, and hypotension. These are consistent with the adverse events reported in the <u>summary of product characteristics</u>. Mahevas et al. 2020 reported a severe side effect of thrombosis during a mean 21 month follow up in 1/15 people who had IV immunoglobulin alone first line. Mecoli et al. 2020 had a shorter follow up period (1 to 2 weeks) and did not report any safety outcomes.

Mecoli et al. 2020 showed that people who were treatment naïve had a greater response to IV immunoglobulin, for the outcomes of MMRSS and skin flexibility, than people who were already on maintenance IV immunoglobulin. However, no statistical analyses were reported for between group differences, only 3 participants were treatment naïve, and outcomes were limited to a 1 to 2 week follow up.

No evidence was identified regarding cost effectiveness of immunoglobulin for people with scleromyxedema.

Conclusion

This evidence review found very low certainty evidence for the efficacy and safety of IV immunoglobulin for people with scleromyxedema.

Four prospective open label case series were included in the review Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020, and Rongioletti et al. 2013. The open label studies had no comparator and the sample sizes were small (n=8, n=25, n=15 and n=11). Mecoli et al. 2020

was designed to assess the acute response to IV immunoglobulin after 1 to 2 weeks (12 people on maintenance therapy [mean 4.2 years], 3 people treatment naïve), Rongioletti et al. 2013 had a mean follow up of 34 months, Guarneri et al. 2017 had a mean follow up of 44 months, and Mahevas et al. 2020 had a mean follow up of 4.3 years. As with all case series, unknown or unmeasured factors may have influenced the findings reported. Case series cannot prove cause and effect and should only be considered hypothesis generating.

The studies found very low certainty evidence that disease activity improved after IV immunoglobulin, although some outcomes were not statistically significant. Both Guarneri et al. 2017 (mean follow up 44 months) and Mecoli et al. 2020 (1 to 2 weeks after IV immunoglobulin) reported statistically significant improvements in mRSSS and MMRSS, respectively. Guarneri et al. 2017 found very low certainty evidence that 2/8 people achieved complete response and 6/8 people achieved partial response during a mean follow up of 44 months. In Mahevas et al. 2020, 10/15 people who had IV immunoglobulin first line achieved a complete response and 5/15 achieved a partial response during a mean follow up of 21 months. However, 2 of these people also experienced failure and 4 had dermatoneuro syndrome or died. Similarly for the people who had IV immunoglobulin second line 2/6 achieved complete response and 4/6 achieved partial response but one person experienced failure and one person had dermatoneuro syndrome or died. In Rongioletti et al. 2013, 3/6 people who had IV immunoglobulin first line achieved partial response. The 5 people who had IV immunoglobulin second, third, or fifth line, all achieved partial response.

Guarneri et al. 2017 provided very low certainty evidence that 5 people experienced a total of 13 adverse events during a mean follow of up 44 months. Mahevas et al. 2020 provided very low certainty evidence that one person who had IV immunoglobulin first line had the severe side effect of thrombosis during a mean 21 month follow up. None of the studies had a comparator group or were powered to detect differences in adverse events, therefore, larger studies with longer follow up durations are needed.

Regarding subgroups of patients who may benefit from treatment more than others, one case series (Mecoli et al 2020) provided evidence relating to treatment response in people who were treatment naïve and people who were already on maintenance IV immunoglobulin. Response to treatment (MMRSS and skin flexibility) was greater in people who were treatment naïve (n=3) compared with people who were on maintenance IV immunoglobulin (n=12). However, no statistical analyses comparing the two subgroups were reported.

No evidence was identified for the important outcomes of withdrawal or reduction of other immunosuppressive treatments, hospital admissions, or survival.

No evidence was identified regarding the cost effectiveness of IV immunoglobulin for people with scleromyxedema.

3. Methodology

Review questions

The review questions for this evidence review are:

- 1. In people with scleromyxedema what is the clinical effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 2. In people with scleromyxedema what is the safety of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 3. In people with scleromyxedema what is the cost-effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 4. From the evidence selected, are there any subgroups of patients that may benefit from intravenous or subcutaneous Ig more than the wider population of interest?
- 5. From the evidence selected, what was the dose, frequency and route of administration of human normal immunoglobulin and duration of treatment?

See <u>Appendix A</u> for the full PICO document.

Review process

The methodology to undertake this review is specified by NHS England in its 'Guidance on conducting evidence reviews for Specialised Services Commissioning Products' (2020).

The searches for evidence were informed by the PICO document and were conducted on 14 February 2023.

See <u>Appendix B</u> for details of the search strategy.

Results from the literature searches were screened using their titles and abstracts for relevance against the criteria in the PICO document. Full text of potentially relevant studies were obtained and reviewed to determine whether they met the inclusion criteria for this evidence review.

See <u>Appendix C</u> for evidence selection details and <u>Appendix D</u> for the list of studies excluded from the review and the reasons for their exclusion.

Relevant details and outcomes were extracted from the included studies and were critically appraised using a checklist appropriate to the study design. See <u>Appendices E</u> and <u>F</u> for individual study and checklist details.

The available evidence was assessed by outcome for certainty using modified GRADE. See <u>Appendix G</u> for GRADE profiles.

4. Summary of included studies

Four papers were identified for inclusion (Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020 and Rongioletti et al. 2013). Table 1 provides a summary of these included studies and full details are given in Appendix E. The included studies were all case series Guarneri et al. 2017 included 8 people, Mahevas et al. 2020 included 33 people, Mecoli et al. 2020 included 15 people and Rongioletti et al. 2013 included 30 people.

Study	Population	Intervention and comparison	Outcomes reported
Guarneri et al.	Participants had characteristic	Intervention	Critical outcome
2017 Case series taly	 skin findings of scleromyxedema confirmed by histopathology and the presence of monoclonal gammopathy Participants must have completed at least six cycles of IV 	IV immunoglobulin 2 g/kg per month, given over 4 or 5 days. IV immunoglobulin cycles were given every 4 to 6 weeks	Systemic involvement/ extracutaneous manifestations
	immunoglobulin within the first 6 months of planned treatment.	No concomitant treatments	Duration of clinical improvement or response to treatment
	 N=8 No comparator group 	Comparison	Progression to dermatoneuro syndrome
	Baseline characteristics:	No comparator	Adverse events
	5 males and 3 females		
	 Mean age 59 years of age (range 35 to 70 years) 		
	 All participants were Caucasian Mean duration of scleromyxedema was 19 months 		
	 (range 6 to 37 months) 6/8 participants had attempted other immunomodulatory therapies that were stopped for unsatisfactory results 		
Mahevas et al.	Participants had to have 3 or	Intervention	Critical outcome
2020 Case series	more of the 4 Rongioletti and Rebora criteria (1: papular eruption, 2: mucin deposition,	IV immunoglobulin 2 g/kg per month	Disease activity Important Outcomes
France	fibroblast proliferation, fibrosis on skin histology, 3: monoclonal gammopathy, 4: the absence of thyroid disease)	15 people first line, 6 people second line, 4 people third line. Comparison	 Progression to dermatoneuro syndrome Adverse events
	• N=25 (15 first line IV immunoglobulin, 6 second line, 4 third line)	No comparator	
	No comparator group		
	Baseline characteristics (reported for the entire cohort [n=33] and include people not on IV immunoglobulin alone, outcomes for these people are not reported in this review):		
	 17 males and 16 females Mean (SD) age 55.4 years (±13.6) 		
	 Mean (SD) age at diagnosis 56.3 years (±13.6, range 28 to 78 years) 		
Aecoli et al. 2020	People diagnosed with scleromyxedema with skin	Intervention	Critical outcome
Case series JSA	involvement. People were either newly diagnosed, treatment naive	Single treatment of IV immunoglobulin 2 g/kg over a period ranging from 2 to 5 days	Disease activityHealth related quality of life
	or undergoing IV immunoglobulin maintenance therapy	All participants had IV immunoglobulin	
	N=15No comparator group	infusions every 4 weeks and then the interval increased to every 6 to 12 weeks once their improvement in skin involvement	
	Baseline characteristics:	had plateaued	
	• 3 males and 12 females		

Table 1: Summary of included studies

	 Mean (SD) age 53 years of age (±11 years) 14 participants were Caucasian 12 participants were receiving maintenance IV immunoglobulin, and 3 participants were treatmen naïve. 		
Rongioletti et al. 2012 Case series Europe, multi- centre	 People diagnosed with scleromyxedema with the following criteria (1: generalised papular and sclerodermoid eruption, 2: mucin deposition, fibroblast proliferation, and fibrosis, 3: monoclonal gammopathy, 4: the absence of thyroid disease) N=11 (6 first line IV immunoglobulin,2 second line, 2 third line, one fifth line) No comparator group Baseline characteristics (reported for the entire cohort [n=30] and include people not on IV immunoglobulin alone outcomes for these people are not reported in this review): 17 males and 13 females Mean age 59 years (range 34 to 86) Mean duration of scleromyxedema at diagnosis 9 months (range 1 to 60) 	Intervention 'Usually' IV immunoglobulin 2 g/kg per month 6 people had IV immunoglobulin alone first line 2 people had IV immunoglobulin second line (after prednisone) 2 people had IV immunoglobulin third line (one person after prednisolone, followed by photopheresis; one person after methotrexate, followed by prednisone) One person had IV immunoglobulin fifth line (after cyclosporine, followed by azathioprine, followed by cyclophosphamide, followed by methotrexate and prednisone) Comparison No comparator	

I

5. Results

In people with scleromyxedema what is the clinical effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?

to standard care al	
Outcome	Evidence statement
Clinical Effectiveness Critical outcomes	
Disease activity Certainty of evidence:	This outcome is important to patients as it reflects how effective the treatment is compared to current standard of care and is a surrogate for control of symptoms and quality of life.
Very low	In total, 4 case series provided evidence relating to disease activity in adults with scleromyxedema. One was designed to assess the acute response to IV immunoglobulin after 1 to 2 weeks, one with a mean follow up of 34 months, one with a mean follow up of 4.3 years.
	In the case series (Guarneri et al. 2017) there were 5 male and 3 female participants with a mean age of 59 years, all participants were Caucasian. The mean duration of scleromyxedema in this case series was 19 months. Six of the 8 participants had attempted other immunomodulatory therapies that were stopped for unsatisfactory results.
	In the cases series (Mahevas et al. 2020) there were 17 male and 16 female participants with a mean age of 55 years. The study included people on all interventions for scleromyxedema. Results are reported in this review for the 25 people had IV immunoglobulin treatment alone. Fifteen people had IV immunoglobulin first line, 6 people second line, and 4 people third line.
	In the case series (Mecoli et al. 2020) there were 12 female and 3 male participants with a mean age of 53 years. Fourteen of the participants were Caucasian, 12 were receiving maintenance IV immunoglobulin, and 3 were treatment naïve.
	In the case series (Rongioletti et al. 2013) there were 17 male and 13 female participants with a mean age of 59 years. The study included people on all interventions for scleromyxedema. Results are reported in this review for the 11 people who had IV immunoglobulin treatment alone within a treatment period. Six people had IV immunoglobulin first line, 2 people second line, 2 people third line, and one person fifth line.
	Follow up 1 to 2 weeks
	In the case series (Mecoli et al 2020) the following outcomes were reported:
	 Mean (SD) MMRSS scores (0 to 60) post treatment reduced from 13.6(±2.6) to 10.3(±1.9) (p=0.003) (VERY LOW)
	 Mean (SD) PGA scores post treatment reduced from 1.4(±0.2) to 1.1(±0.2) (p=0.100) (VERY LOW)
	 Mean (SD) body surface area % affected post treatment reduced from 36(±38%) to 25(±29%) (p=0.099) (VERY LOW)
	 Mean (SD) skin scale pain scores post treatment reduced from 1.8(±2.4) to 1.4(±2.4) (p=0.252) (VERY LOW)
	 Mean (SD) skin scale flexibility scores post treatment reduced from 5.4(±3.5) to 3.3(±3.1) (p=0.013). (VERY LOW)
	 Mean (SD) skin scale softening scores post treatment reduced from 4.9(±3.4) to 2.7(±2.5) (P=0.022) (VERY LOW)
	 Mean skin scale global (0 to 10) post treatment reduced from 4.5(±3.3) to 2.7(±2.4) (p=0.029) (VERY LOW)
	Follow up at 2 months to 11 years (mean 33.5 months)

	In the case series (Rongioletti et al. 2013) the following outcomes were reported:
	• First line: 3/6 achieved complete response, 3/6 achieved partial response
	• Second line: 0/2 achieved complete response, 2/2 achieved partial response
	• Third line: 0/2 achieved complete response, 2/2 achieved partial response
	 Fifth line: 0/1 achieved complete response, 1/1 achieved partial response (VERY LOW)
	Follow up at 15 months to 87 months (mean 44 months)
	In the case series (Guarneri et al. 2017) the following outcomes were reported:
	 2/8 (25%) participants achieved complete response and 6/8 (75%) achieved partial response. No statistical analysis reported. (VERY LOW)
	 mRSSS (0 to 182) reduced from 82.38 (37 to 145, SD 40.76) to 14.88 (0 to 37, SD 12.99) (p=0.012). (VERY LOW)
	• 5 participants had partial improvement (score 1) and 3 had full improvement (score 2) in their PGA scores. (VERY LOW)
	Follow up at 6 months to 13 years (mean 4.3 years)
	In the case series (Mahevas et al. 2020) the following outcomes were reported:
	• First line (mean follow up 21 months): 10/15 achieved complete response, 5/15 achieved partial response
	 Second line (mean follow up 24 months): 2/6 achieved complete response, 4/6 achieved partial response
	• Third line (mean follow up 28 months): 0/4 achieved complete response, 4/4 achieved partial response (VERY LOW)
	Very low certainty evidence from 4 case series suggests disease activity scores and the number of people who had complete or partial response improved in people with scleromyxedema treated with IV immunoglobulin. However, some outcomes did not reach statistical significance and it is unknown if any results are clinically meaningful.
Systemic involvement/ extracutaneous manifestations	This outcome is important to patients because systemic involvement is linked to severe and/or untreated disease and has a large impact on quality of life and function.
Certainty of evidence:	In total, one case series (Guarneri et al. 2017) provided evidence relating to
Very low	systemic involvement with a mean follow up of 44 months.
	All systemic symptoms (including neurologic, dysphagia, dyspnoea, arthralgias) improved in 6/8 participants and 2/8 participants continued to experience arthralgias. (VERY LOW)
	Very low certainty evidence from one case series provided evidence that systemic involvement and extracutaneous manifestations improved after treatment with IV immunoglobulin in 6/8 participants.
Health related quality of life (HRQL)	This outcome is important to patients because it provides a holistic evaluation and indication of the patient's general health and their perceived well-being and their ability to participate in activities of daily living. This outcome is therefore a key indicator of the patient's perspective of effectiveness of treatment.
	1

Certainty of evidence:	One case series (Mecoli et al 2020) provided evidence relating HRQL with a follow up period of 1 to 2 weeks.
Very low	
	Mean (SD) HAQ-DI scores reduced after treatment with IV immunoglobulin from 0.62(±0.7) to 0.54(±0.2) (p=0.403). (VERY LOW)
	Very low certainty evidence from one case series provided evidence that the mean HAQ-DI score reduced 1 to 2 weeks after treatment with IV immunoglobulin, but this was not statistically significant.
Important outcomes	
Duration of clinical	This outcome is important to patients because it gives an indicator of how long the effect of this intervention may last, and how long they can expect to be treated for.
Certainty of evidence:	One case series (Guarneri et al. 2017) provided evidence of the duration of clinical improvement or response to treatment.
Very low	Maintenance infusions (every 4 to 6 weeks) were needed in 6/8 participants to maintain disease control. VERY LOW)
	Two participants who obtained complete response, stopped treatment after 7 and 11 months but relapses occurred after 6 and 25 months, respectively, and IV immunoglobulin was restarted. 1/8 participant developed dermatoneuro syndrome after stopping IV immunoglobulin voluntarily; complete recovery of the neurological symptoms was seen after the reintroduction of IV immunoglobulin after one cycle in 3 weeks. (VERY LOW)
	Very low certainty evidence from one case series showed 6/8 participants needed maintenance infusions to maintain disease control. The 2 participants who obtained complete response stopped treatment after 7 and 11 months but relapses occurred after 6 and 25 months, respectively. Reintroduction of IV immunoglobulin was successful in both cases.
Withdrawal or reduction of other immunosuppressive treatments	This outcome is important to patients because it reduces the burden of treatment and reduces the side effect potential of immunosuppressive medication.
Certainty of evidence:	No evidence was identified for this outcome.
Not applicable	
Progression to	This outcome is important to patients because it is one of the most severe
dermatoneuro syndrome	complications of untreated disease and often causes intensive care admission and long-term morbidity and mortality if untreated.
Certainty of evidence:	
Not applicable	Two case series (Guarneri et al. 2017 and Mahevas et al. 2020) provided evidence of the progression to dermatoneuro syndrome.
	Follow up at mean 21 months
	 4/15 people who had first line IV immunoglobulin had progressed to dermatoneuro syndrome, cardiac injury, or death
	 1/6 people who had second line IV immunoglobulin had progressed to dermatoneuro syndrome, cardiac injury, or death (VERY LOW)
	Follow up at 15 months to 87 months (mean 44 months)
	• Two of 8 (25%) participants progressed to dermatoneuro syndrome (one person before IV immunoglobulin [spontaneously recovered], and one person after stopping IV immunoglobulin voluntarily [restarting IV immunoglobulin led to a complete recovery of the

	neurological involvement]). No statistical analysis reported. (VERY LOW)
	Very low certainty evidence from one case series showed that 2/8 participants progressed to dermatoneuro syndrome and, in another case series, 4/15 participants who had IV immunoglobulin first line and 1/6 second line progressed to dermatoneuro syndrome, cardiac injury, or death.
Hospital admissions	This can provide objective evidence of treatment response and is relevant to patients because it has a significant impact on their life and is related to disease
Certainty of evidence:	severity.
Not applicable	No evidence was identified for this outcome.
Survival	This outcome is important to patients because it reflects how long people live after treatment, although it does not provide information about their health and wellbeing
Certainty of evidence:	during that time.
Not applicable	No evidence was identified for this outcome.
Safety	
Adverse drug reactions	Safety is important to patients as it reflects the risks involved in what is likely to be a long term treatment. This allows a risk benefit assessment to be undertaken.
Certainty of evidence:	
Very low	One case series (Guarneri et al. 2017) provided evidence of adverse drug events (number of people) after a mean follow up of 44 months. The case series reports 13 adverse events in 5 people. Asthenia (4), headache (3), exfoliative keratolysis (2), acute hypertensive episodes (1), fever (1), dizziness (1), hypotension (1). (VERY LOW)
	One case series (Mahevas et al. 2020) provided evidence of serious side effects during a mean follow up of 21 months. 1/15 people who had IV immunoglobulin first line had thrombosis. (VERY LOW)
	Very low certainty evidence from one case series showed that 13 adverse events occurred in 5 of 8 participants. Very low certainty evidence from one case series showed that 1/15 people had a serious side effect.

Abbreviations

HAQ-DI, health assessment questionnaire disability index; IV, intravenous; MMRSS, modification of the modified Rodnan skin score for scleromyxedema; PGA, physician global assessment; SD, standard deviation

In people with scleromyxedema what is the cost-effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?

Outcome	Evidence statement
Cost- effectiveness	No evidence was identified for this outcome

From the evidence selected, are there any subgroups of patients that may benefit from intravenous or subcutaneous Ig more than the wider population of interest?

Outcome Evidence statement

E	
Response to treatment in	One case series (Mecoli et al 2020) provided evidence relating to treatment
people who were treatment	response in people who were treatment naïve and people who were on maintenance
naïve and in people on	IV immunoglobulin.
maintenance IV	
immunoglobulin	NMDSS reduced from 20.6 \pm 5.1 of baseling to 12.2 \pm 4.7 ofter treatment (p. 0.002) in
Inimunogiobulin	MMRSS reduced from 20.6 \pm 5.1 at baseline to 13.3 \pm 4.7 after treatment (p=0.002) in the treatment naïve group (n=3) and reduced from 11.9 \pm 10.4 to 9.5 \pm 8.1 (p=0.034) in the people on maintenance IV immunoglobulin (n=12). No statistical analyses comparing the two subgroups were reported.
	Mean skin scale flexibility (0 to 10) reduced from 7.4 \pm 1.0 at baseline to 0.5 \pm 0.5 after treatment in the treatment naïve group and reduced from 4.9 \pm 3.6 to 3.9 \pm 3.0 in the people on maintenance IV immunoglobulin. No statistical analyses reported.
	This study provides evidence response to treatment in people who were treatment naïve and in people on maintenance IV immunoglobulin. Response to treatment was greater in people who were treatment naïve compared with people who were on maintenance IV immunoglobulin. However, no conclusions can be drawn.

From the evidence selected, what was the dose, frequency, and route of administration of human normal immunoglobulin and duration of treatment?

Dosage
IV immunoglobulin 2 g/kg per month, given over 4 or 5 days.
IV immunoglobulin cycles were given every 4 to 6 weeks, depending on clinical response.
Mean dose of IV immunoglobulin 2 g/kg per month. No other information provided.
IV immunoglobulin 2 g/kg given over 2 to 5 days.
After the first infusion (for which outcomes are reported after 1 to 2 weeks), all participants had IV immunoglobulin infusions every 4 weeks and then the interval increased to every 6 to 12 weeks once their improvement in skin involvement had plateaued.
Usually' 2 g/kg per month. No other information provided.

6. Discussion

The evidence review included 4 case series (Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020, and Rongioletti et al. 2013). It is difficult to conduct high quality studies in rare diseases such as scleromyxedema as there are few eligible participants and previous treatment regimens can differ substantially. All included studies have many limitations. For example, there were no comparators, Mahevas et al. 2020 and Rongioletti et al. 2013 were mainly retrospective, and the sample sizes were small (n=8, n=25, n=15, and n=11, respectively). All outcomes were considered to have very low certainty using modified GRADE.

No evidence was found comparing IV immunoglobulin with standard care. The studies were prospective and open label. Consequently, are subject to bias due to unblinding of participants and investigators, which can impact on patient reported outcomes or investigator assessed outcomes. Many of the reported outcomes could be considered subjective, including pain scores, Rodnan Skin Scores, and PGA, and are therefore subject to bias.

As with many small case series, the studies were not powered for statistical hypothesis testing and the data should be regarded as descriptive only. Case series are subject to bias, such as selection bias and observation bias, and confounding, and cannot prove that an intervention (such as IV immunoglobulin) caused a particular outcome, only that it is associated with that outcome.

In Mecoli et al. 2020, outcomes were reported 1 to 2 weeks after a single dose of IV immunoglobulin. Therefore, longer term outcomes, including complete or partial response, which are typically seen over several treatments, were not available for the 3 treatment naïve participants. Before treatment comparisons were also not available for the 12 participants on maintenance treatment. In Guarneri et al. 2017 (n=8), outcomes were reported at the last follow up assessment which ranged from 15 to 87 months. In this case series, 2/8 people achieved complete response and 6/8 people achieved partial response. In Mahevas et al. 2020, 10/15 people who had IV immunoglobulin first line achieved a complete response and 5/15 achieved a partial response. However, 2 of these people also experienced failure and 4 had dermatoneuro syndrome or died. Similarly for the people who had IV immunoglobulin second line 2/6 achieved complete response and 4/6 achieved partial response but one person experienced failure and one person had dermatoneuro syndrome or died. 'Failure' was not defined in the study and the definitions of response were subjective. In Rongioletti et al. 2013, 3/6 people who had IV immunoglobulin first line achieved complete response and 3/6 achieved partial response. The 5 people who had IV immunoglobulin second, third, or fifth line, all achieved partial response. Complete response was defined as disappearance of symptoms and no detectable findings on examination, however the outcome of partial response (decrease in skin changes and improvement in systemic symptoms) could be considered subjective.

The critical outcome of health related quality of life was only reported in the case series with a 1 to 2 week follow up (Mecoli et al. 2020). No significant difference was reported in the HAQ-DI. It is likely that a longer term follow up is needed to observe any differences.

Guarneri et al. 2017 reported adverse events over the mean 44 month follow up period. Five people experienced a total of 13 adverse events including asthenia, headache, exfoliative keratolysis, acute hypertensive episodes, fever, dizziness, and hypotension. These are consistent with the adverse events reported in the <u>summary of product characteristics</u>. Mahevas et al. 2020 reported a severe side effect of thrombosis during a mean 21 month follow up in 1/15 people who had IV immunoglobulin alone first line. Mecoli et al. 2020 had a shorter follow up period (1 to 2 weeks) and did not report any safety outcomes.

Mecoli et al. 2020 showed that people who were treatment naïve had a greater response to IV immunoglobulin, for the outcomes of MMRSS and skin flexibility, than people who were already on maintenance IV immunoglobulin. However, no statistical analyses were reported for between group differences, only 3 participants were treatment naïve, and outcomes were limited to a 1 to 2 week follow up.

No evidence was identified regarding cost effectiveness of immunoglobulin for people with scleromyxedema.

7. Conclusion

This evidence review found very low certainty evidence for the efficacy and safety of IV immunoglobulin for people with scleromyxedema.

Four prospective open label case series were included in the review Guarneri et al. 2017, Mahevas et al. 2020, Mecoli et al. 2020, and Rongioletti et al. 2013. The open label studies had no comparator and the sample sizes were small (n=8, n=25, n=15 and n=11). Mecoli et al. 2020 was designed to assess the acute response to IV immunoglobulin after 1 to 2 weeks (12 people on maintenance therapy [mean 4.2 years], 3 people treatment naïve), Rongioletti et al. 2013 had a mean follow up of 34 months, Guarneri et al. 2017 had a mean follow up of 44 months, and Mahevas et al. 2020 had a mean follow up of 4.3 years. As with all case series, unknown or unmeasured factors may have influenced the findings reported. Case series cannot prove cause and effect and should only be considered hypothesis generating.

The studies found very low certainty evidence that disease activity improved after IV immunoglobulin, although some outcomes were not statistically significant. Both Guarneri et al. 2017 (mean follow up 44 months) and Mecoli et al. 2020 (1 to 2 weeks after IV immunoglobulin) reported statistically significant improvements in mRSSS and MMRSS, respectively. Guarneri et al. 2017 found very low certainty evidence that 2/8 people achieved complete response and 6/8 people achieved partial response during a mean follow up of 44 months. In Mahevas et al. 2020, 10/15 people who had IV immunoglobulin first line achieved a complete response and 5/15 achieved a partial response during a mean follow up of 21 months. However, 2 of these people also experienced failure and 4 had dermatoneuro syndrome or died. Similarly for the people who had IV immunoglobulin second line 2/6 achieved complete response and 4/6 achieved partial response but one person experienced failure and one person had dermatoneuro syndrome or died. In Rongioletti et al. 2013, 3/6 people who had IV immunoglobulin first line achieved partial response. The 5 people who had IV immunoglobulin second, third, or fifth line, all achieved partial response.

Guarneri et al. 2017 provided very low certainty evidence that 5 people experienced a total of 13 adverse events during a mean follow of up 44 months. Mahevas et al. 2020 provided very low certainty evidence that one person who had IV immunoglobulin first line had the severe side effect of thrombosis during a mean 21 month follow up. None of the studies had a comparator group or were powered to detect differences in adverse events, therefore, larger studies with longer follow up durations are needed.

Regarding subgroups of patients who may benefit from treatment more than others, one case series (Mecoli et al 2020) provided evidence relating to treatment response in people who were treatment naïve and people who were already on maintenance IV immunoglobulin. Response to treatment (MMRSS and skin flexibility) was greater in people who were treatment naïve (n=3) compared with people who were on maintenance IV immunoglobulin (n=12). However, no statistical analyses comparing the two subgroups were reported.

No evidence was identified for the important outcomes of withdrawal or reduction of other immunosuppressive treatments, hospital admissions, or survival.

No evidence was identified regarding the cost effectiveness of IV immunoglobulin for people with scleromyxedema.

Appendix A PICO document

The review questions for this evidence review are:

- 1. In people with scleromyxedema what is the clinical effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 2. In people with scleromyxedema what is the safety of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 3. In people with scleromyxedema what is the cost-effectiveness of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care alone?
- 4. From the evidence selected, are there any subgroups of patients that may benefit from intravenous or subcutaneous Ig more than the wider population of interest?
- 5. From the evidence selected, what was the dose, frequency, and route of administration of human normal immunoglobulin and duration of treatment?

P –Population and Indication	People with scleromyxedema [may be known as scleromyxoedema, generalised and sclero-dermoid lichen myxedematosus or Arndt–Gottron disease. The condition can be abbreviated to SMX]
	Human normal immunoglobulin (IVIg/SCIg) as monotherapy or in addition to current standard care Current standard care includes but is not limited to the following immunosuppressant options:
I – Intervention	cyclophosphamide, mycophenolate mofetil, methotrexate, hydroxychloroquine, melphalan, ciclosporin, thalidomide, lenalidomide, bortezomib, stem cell transplant, plasmapheresis, systemic corticosteroids. Phototherapy and other similar treatments may also be used.
	[Human normal immunoglobulin administered at any point in the treatment pathway]
	[Dose varies according to clinician choice and patient factors so all doses should be included. For information, the most frequently used starting dose is 2g/kg]
C – Comparator(s)	Current standard care [No defined standard of care exists in the UK in this patient group, however terms such as standard of care,
	optimised medical management may be used in the international literature]
O – Outcomes	Clinical Effectiveness

Unless stated for the outcome, minimum clinically important differences (MCIDs) are unknown. Outcomes ideally measured at 6, 12, 24 months as well as long-term outcomes. Critical to decision making • Disease activity This outcome is important to patients as it reflects how effective the treatment is compared to current standard of care and is a surrogate for control of symptoms and quality of life. [Rodnan score/modified Rodnan score/modified Rodnan skin score/ modification of the modified Rodnan skin score/ modified Rodnan score system for scleromyxedema is often used to quantify disease activity in this condition. Disease activity may also be measured by body surface area involvement, skin thickening, skin flexibility, skin softening, pruritis, papular involvement, photographic assessment of disease activity, skin pain scale, skin scale global, visual analogue scale. Disease activity can be linked to presence and severity of skin symptoms. Patient reported measures as well as physician rated measures are both relevant. Physician global assessment (PGA) can be used as a generalised score of disease severity. Reduction in disease activity may also be termed as complete or partial clinical response/remission] Systemic involvement/extracutaneous manifestations This outcome is important to patients because systemic involvement is linked to severe and/or untreated disease and has a large impact on quality of life and function. [Systemic involvement includes, but is not limited to; paraesthesia, neuropathy, carpal tunnel syndrome, cardiomyopathy, myocardial ischaemia, arthralgia, myositis, haematological malignancy, pulmonary fibrosis, dysphagia, central nervous system involvement (e.g. coma, encephalopathy, seizures). Systemic involvement is also indicated by the presence of absence of symptoms such as difficulty swallowing, difficulty opening mouth, feeding or nutrition difficulties, shortness of breath and reduced mobility. Patient reported measures as well as physician rated measures are both relevant.] Health related quality of life (HRQL)

This outcome is important to patients because it provides a holistic evaluation and indication of the patient's general health and their perceived well-being and their ability to participate in activities of daily living. This outcome is therefore a key indicator of the patient's perspective of effectiveness of treatment
[Other terms used to describe or indicate quality of life include but are not limited to; patient-reported quality of life outcomes, health related quality of life. Examples of metrics to assess quality of life include but are not limited to: Short Form (SF-36), EuroQuality of Life Five Dimensions (EQ-5D), Dermatological life quality index (DLQI), Health assessment questionnaire-disability index (HAQ-DI).
Other methods of assessing quality of life include but are not limited to subjective/self-reported/carer reported quality of life experiences.]
Important to decision-making:
Duration of clinical improvement or response to treatment
This outcome is important to patients because it gives an indicator of how long the effect of this intervention may last, and how long they can expect to be treated for.
[Terms used to describe this may include, but are not limited to; time to recurrence, remission duration, time to relapse, time to flare.]
Withdrawal or reduction of other immunosuppressive treatments
This outcome is important to patients because it reduces the burden of treatment, and reduces the side effect potential of immunosuppressive medication
[Treatments include but are not limited to cyclophosphamide, mycophenolate mofetil, melphalan, ciclosporin, steroids.]
Progression to dermatoneuro syndrome
This outcome is important to patients because it is one of the most severe complications of untreated disease and often causes intensive care admission and long-term morbidity and mortality if untreated.
[Dermatoneuro syndrome is defined as coma, encephalopathy and/or seizure (Mecoli et al., 2020)]

	Hospital admissions
	This can provide objective evidence of treatment response and is relevant to patients because it has a significant impact on their life and is related to disease severity.
	[Admissions may be secondary to feeding and nutritional difficulties requiring, for example, PEG insertion. Dermatoneuro syndrome or other neurological involvement such as seizures can also lead to admission]
	Survival
	This outcome is important to patients because it reflects how long people live after treatment, although it does not provide information about their health and wellbeing during that time.
	[Other terms used to describe or indicate survival include, but are not limited to, overall survival, survival rate, freedom from death, death]
	<u>Safety</u>
	 Complications of human normal immunoglobulin (IVIg/SCIg) therapy
	Safety is important to patients as it reflects the risks involved in what is likely to be a long term treatment. This allows a risk benefit assessment to be undertaken
	[Other terms used to describe or indicate safety include, but are not limited to; adverse events, serious/ major adverse events.
	This may include but is not limited to; death, aseptic meningitis, myocardial infarction, need for intensive care admission, haemolysis, fever, chills, rash, headache]
	Cost effectiveness
Inclusion criteria	
Study docian	Systematic reviews, randomised controlled trials, controlled clinical trials, cohort studies.
Study design	If no higher-level quality evidence is found, case series can be considered.
Language	English only
Patients	Human studies only

Age	All ages
Date limits	2013 – 2023
Exclusion criteria	
Publication type	Conference abstracts, non-systematic reviews, narrative reviews, commentaries, letters, editorials, pre prints and guidelines
Study design	Case reports, resource utilisation studies

Appendix B Search strategy

Medline, Embase and the Cochrane Library were searched limiting the search to papers published in English language in the last 10 years. Conference abstracts, commentaries, letters, editorials and case reports were excluded.

Search dates: 14 February 2023

Medline

1 Scleromyxedema/ 292

2 (Scleromyxedema* or scleromyxoedema* or scleromyxooedema* or arndt-gottron or (lichen adj (fibromucinoidosus or myxedematosus or myxoedematosus or myxooedematosus)) or ((mucinosis or myxedema or myxoedema or myxooedema) adj2 (papulosa or papulosum or popular))).tw. 589

- 3 or/1-2 654
- 4 Immunoglobulins, Intravenous/ or Immunoglobulins/ 59623
- 5 ((intravenous* or subcutanceous*) and immunoglobulin).tw. 14376
- 6 ("IVIg/SCIg" or (IVIg adj SCIg)).tw. 20
- 7 or/4-6 65696
- 8 3 and 7 82
- 9 limit 8 to english language 72
- 10 limit 9 to (letter or historical article or comment or editorial or news) 9
- 11 9 not 10 63
- 12 limit 11 to yr="2013 -Current" 37

Embase

1 scleromyxedema/ 841

2 (Scleromyxedema* or scleromyxoedema* or scleromyxooedema* or arndt-gottron or (lichen adj (fibromucinoidosus or myxedematosus or myxoedematosus or myxooedematosus)) or ((mucinosis or myxedema or myxoedema or myxooedema) adj2 (papulosa or papulosum or popular))).tw.726

- 3 or/1-2 1018
- 4 immunoglobulin/ or human immunoglobulin/ 143312
- 5 ((intravenous* or subcutanceous*) and immunoglobulin).tw. 26426
- 6 ("IVIg/SCIg" or (IVIg adj SCIg)).tw. 49
- 7 or/4-6 148604
- 8 3 and 7 244
- 9 limit 8 to english language 218
- 10 9 not (letter or editorial).pt. 197
- 11 limit 10 to yr="2013 -Current" 116
- 12 (conference abstract* or conference review or conference paper or conference
- proceeding).db,pt,su. 5454108
- 13 11 not 12 92

Cochrane Library

#1 [mh ^Scleromyxedema] 0

#2 (Scleromyxedema* or scleromyxoedema* or scleromyxooedema* or arndt-gottron or (lichen NEAR (fibromucinoidosus or myxedematosus or myxoedematosus or


myxooedematosus)) or ((mucinosis or myxedema or myxoedema or myxooedema) NEAR/2 (papulosa or papulosum or popular))):ti,ab 0

- #3 {or #1-#2} 0
 - (did not continue with strategy as there were 0 results for condition)

Appendix C Evidence selection

The literature searches identified 90 references. These were screened using their titles and abstracts and 5 references were obtained in full text and assessed for relevance. Of these, 4 references are included in the evidence summary. The remaining reference was excluded and is listed in Appendix D.

Figure 1- Study selection flow diagram



References submitted with Preliminary Policy Proposal

Reference	Paper selection - decision and rationale if excluded
	Included
F., Wigley, F. M., & Hummers, L. K. (2020). Clinical and	
Molecular Phenotyping in Scleromyxedema Pretreatment	
and Posttreatment With Intravenous Immunoglobulin.	
Arthritis Care and Research, 72(6).	
Guarneri, A., Cioni, M., & Rongioletti, F. (2017). High-	Included
dose intravenous immunoglobulin therapy for	
scleromyxoedema: a prospective open-label clinical trial	
using an objective score of clinical evaluation system.	
Journal of the European Academy of Dermatology and	
Venereology, 31(7).	
Rongioletti, F., Merlo, G., Cinotti, E., Fausti, V., Cozzani,	Included
E., Cribier, B., Metze, D., Calonje, E., Kanitakis, J.,	
Kempf, W., Stefanato, C. M., Marinho, E., & Parodi, A.	
(2013). Scleromyxedema: A multicenter study of	
characteristics, comorbidities, course, and therapy in 30	
patients. Journal of the American Academy of	
Dermatology, 69(1).	

Appendix D Excluded studies table

Study reference	Reason for exclusion
Haber R, Bachour J, Gemayel M. (2020) Scleromyxedema treatment: a systematic review and update. International Journal of Dermatology, 59, 1191- 1201.	Excluded – more complete evidence available from primary studies

Appendix E Evidence table

Study details	Population	Interventions	Study outcomes	Appraisal and funding
Full citation Guarneri A, Cioni M, Rongioletti F	Inclusion criteria Participants had characteristic	Interventions	Critical outcomes Disease activity	This study was appraised using the Joanna Briggs Institute checklist for case series
(2017) <u>High-dose intravenous</u> immunoglobulin therapy for	skin findings of	2 g/kg per month, given over 4 or 5 days. Depending on clinical response,	2/8 (25%) achieved complete response and 6/8	1.Yes
scleromyxedema: a prospective open-label clinical trial using an	histopathology and the presence of monoclonal	IV immunoglobulin cycles were given		2.Yes
objective score for clinical evaluation system. JEADV 32, 1157-1160		therapy was finished when a complete response was observed for at least	mRSSS reduced from 82.38 (37 to 145, SD 40.76) to 14.88 (0 to 37, SD 12.99) (p=0.012)	3.Yes
Study location	Participants needed to have completed at least 6 cycles of	8 weeks.	PGA scores: 3/8 had full improvement and 5/8	4.Yes
Genoa, Italy	IV immunoglobulin infusion within the first 6 months of	The mean duration of IV	had partial improvement Svstemic involvement/extracutaneous	5.Yes
Study type	planned treatment	immunoglobulin was 36.5 months (range 7 to 74 months).	manifestations	6.Yes 7.Yes
Prospective case series	Exclusion Criteria None reported	Participants were followed up for a minimum of 15 months to a maximum	All systemic symptoms improved with IV immunoglobulin except arthralgias in 2/8 participants. No statistical analysis reported	8.Yes
Study aim The aim of the study was 'to evaluate	Total sample size	of 87 months (mean 44 months)	Important outcomes	9.Yes
the safety and efficacy of high-dose intravenous immunoglobulin for the	8 people	Comparators No comparator	Duration of clinical improvement or response to treatment	10.Yes
management of scleromyxedema prospectively using an objective score'	No. of participants in each treatment group		6/8 (75%) maintenance infusions were needed	Other comments: The study is a case series and, as such, is rated as poor in the hierarchy of study designs. However, there are few
Study dates	All 8 participants received IV immunoglobulin		2/8 (25%) who obtained complete response,	eligible participants for studies using new treatments in rare diseases (such as
Between January 2012 and March 2015	Baseline characteristics		relapses occurred after 6 and 25 months,	scleromyxedema), meaning it is difficult to conduct high quality studies. Key limitations are
	5 males and 3 females		respectively, and IV immunoglobulin was restarted	that treatment with IV immunoglobulin was open label, there was no comparator, and the
	All 8 participant were Caucasian Mean age of 59 years of age		Progression to dermatoneuro syndrome	sample size was small (n=8). As with many case series, the study was not powered for
	(35 to 70 years)		syndrome (one person before IV	statistical hypothesis testing and the data should be regarded as descriptive only.
	The mean duration of scleromyxedema was 19 months (6 to 37 months) 6/8 participants had attempted		immunoglobulin [spontaneously recovered], and one person after stopping IV immunoglobulin voluntarily [restarting IV immunoglobulin led to a complete recovery of the neurological involvement])	
	other immunomodulatory therapies that were stopped for unsatisfactory results.		Safety 13 adverse events in 5 people	Source of funding: Not reported

al. (2020) Plasma cell-directed parmopathy-associated gammopathy, essociated spectromycdema. Blood.155(1), 2- mucin deposition, 2- mucin depositio	gammopathy-associated scleromyxedema. Blood;135(14) 1101-1110eruption, 2: mucin deposition, fibroblast proliferation, fibrosis on skin histology, 3: monoclonal gammopathy, 4: the absence of thyroid disease)No comparators No comparatorStudy locationExclusion CriteriaNone reportedStudy typeNone reportedRetrospective case seriesTotal sample sizeStudy aim33 people in the entire cohort but only 25 had IV immunoglobulin alone (15 first line, 6 second line, 4 third line).	blete and partial remission1. Yesthe (mean follow up 21 months): 10/152. Yeseved complete response, 5/15 achieved3. Yesal response3. Yestine (mean follow up 24 months): 2/64. No
Briggs Institute checklist for case series	gammopathy associated scleromyxedemaNo. of participants in each treatment groupStudy dates25 people had IV immunoglobulinBetween January 1999 and June 2018Baseline characteristicsBaseline characteristics (reported for the entire cohort [n=33] and include people not on IV immunoglobulin alone, outcomes for these people are not reported in this review):•17 males and 16 females•Mean (SD) age 35.4 years (±13.6)•Mean (SD) age at diagnosis 56.3 years (±13.6, range 28 to	 5.Yes 5.Yes 6.Yes 6.Yes 7.Yes 8.No 9.Yes 9.Yes 10.No 0.ther comments: The study is a case series and, as such, is rated as poor in the hierarchy of study designs. However, there are few eligible participants for studies using new treatments in rare diseases (such as scleromyxedema), meaning it is difficult to conduct high quality studies. Key limitations are that the study was retrospective, treatment with IV immunoglobulin had the severe side effect of nbosis 6.Yes 7.Yes 8.No 9.Yes 10.No 0.ther comments: The study is a case series and, as such, is rated as poor in the hierarchy of study designs. However, there are few eligible participants for studies using new treatments in rare diseases (such as scleromyxedema), meaning it is difficult to conduct high quality studies. Key limitations are that the study was retrospective, treatment with IV immunoglobulin was open label, there was no comparator, and the sample size was small. As with many case series, the study was not powered for statistical hypothesis testing and the data should be regarded as descriptive only. Case series have no comparators, and unknown or unmeasured factors may have influenced the findings reported. Case series cannot prove cause and effect and should only be considered hypothesis generating. Source of funding: Not reported
Briggs Institute checklist for case series	Mahevas T, Arnult B, Bouaziz JD et Participants had to have 3 or IV immunoglobulin fin al. (2020) Plasma cell-directed more of the 4 Rongioletti and third line 2 g/kg per n	

Mecoli CA., Talbot CC., Fava A et al.	People diagnosed with	N/ immuneglobulin 2 g/kg over a pariod		1.Yes
		IV immunoglobulin 2 g/kg over a period	Disease activity	1. res
(2020) <u>Clinical and molecular</u>		ranging from 2 to 5 days	Mean PGA scores post treatment reduced from	2 Voc
phenotyping in scleromyxedema pre-		All participants had IV immunoglobulin	1.4+0.2 to $1.1+0.2$ (p=0.100)	2.165
and post- treatment with intravenous			····=0:= to ····=0:= (p · 0::00)	3.Yes
immunoglobulin. Arthritis Care and	in the strate george	infusions every 4 weeks and then the	Mean body surface area affected post treatment	0.163
Research, 72(6);761-767.	in in an ogroballin mainton an oo	interval increased to every 6 to	reduced from 36±38% to 25±29% (p=0.099)	4.Yes
Study location		12 weeks once their improvement in		1.100
olddy location		skin involvement had plateaued	Mean skin scale pain scores post treatment	5.Yes
Baltimore, Maryland, USA	Exclusion Criteria	Comparators	reduced from 1.8±2.4 to 1.4±2.4 (p=0.252)	
	None reported	Comparators	Mean skin scale flexibility scores (0 to 10) (lower	6.Yes
Study type		No comparator	is better) post treatment reduced from 5.4 ± 3.5 to	
	Total sample size			7.Yes
Prospective case series			3.3±3.1 (p=0.013)	
	15 people		Mean skin scale softening scores (0 to10) (lower	8.Yes
Study aim			is better) post treatment reduced from 4.9 ± 3.4 to	
The study aimed 'to explore whether	No. of participants in each		2.7±2.5 (P=0.022)	9.Yes
IV immunoglobulin would introduce a	treatment group			
measurable biologic effect	All 15 participants received IV		Mean skin scale global (0 to 10) post treatment	10.Yes
0			reduced from 4.5±3.3 to 2.7±2.4 (p=0.029)	
corresponding with clinical improvement'.	immunoglobulin			Other comments: The study is a case series
	Baseline characteristics		Mean MMRSS scores (0 to 60) post treatment	and, as such, is rated as poor in the hierarchy
Study dates	Dasenne characteristics		reduced from 13.6±2.6 to 10.3±1.9 (p=0.003)	of study designs. However, there are few
Sludy dales	12/15 participants (80%) were		The second data collection point was	eligible participants for studies using new
Not reported	female and 3/15 participants			treatments in rare diseases (such as
	(20%) were male		approximately 1 to 2 weeks after IV immunoglobulin was completed	scleromyxedema), meaning it is difficult to
	()		immunoglobulin was completed	conduct high quality studies. Key limitations are
	Mean age (±SD) 53 years		Health related quality of life	that treatment with IV IMMUNOGLOBULIN was
	±11 years			open label, there was no comparator, and the
	,		Mean HAQ-DI scores post treatment reduced	sample size was small (n=15). As with many
	14 participants (93%) were		from 0.62±0.7 to 0.54±0.2 (p=0.403)	case series, the study was not powered for
	Caucasian			statistical hypothesis testing and the data
				should be regarded as descriptive only.
	12 participants (80%) were			
	receiving maintenance IV			Case series have no comparators, and
	immunoglobulin, and			unknown or unmeasured factors may have
	3 participants (20%) were			influenced the findings reported. Case series
	treatment naïve.			cannot prove cause and effect and should only
				be considered hypothesis generating.
	The average duration on IV			· · · · · · · · · · · · · · · · · · ·
	immunoglobulin for the 12			Source of funding: Not reported
	participants on maintenance			- ·
	therapy at baseline was			
	4.2±2.5 years, and the average			
	number of infusions was 24			
	The mean PGA score was			
	1.4 ± 0.2 , the mean HAQ-DI			
	score was 0.62±0.7 and the			
	mean MMRSS was 13.6±2.6			
	The mean body surface area			
	affected was 36±38%			
	allected Was JU±JO%			

Full citation	The mean skin scale pain score was 1.8±2.4, the mean skin scale flexibility was 5.4±3.5, the mean skin scale softening was 4.9±3.4 and the mean skin scale global was 4.5±3.3 No adjuvant therapy was taken by participants during the study	Intervention	Critical outcomes	This study was appraised using the Joanna
Rongioletti F, Merlo G, Cinotti E et al (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol, 69(1):66-72. Study location Multi-centre Europe Study type Retrospective case series Study aim 'To describe the characteristics of patients with scleromyxedema regarding demographics, clinical characteristics, comorbidities, therapeutic interventions, and course.' Study dates January 2000 to April 2012	scleromyxedema with the following criteria (1: generalised papular and sclerodermoid eruption, 2: mucin deposition, fibroblast proliferation, and fibrosis, 3: monoclonal gammopathy, 4: the absence of thyroid disease)	month [°] 6 people had IV immunoglobulin alone 1 st line	Disease activity First line: 3/6 achieved complete response, 3/6 achieved partial response Second line: 0/2 achieved complete response, 2/2 achieved partial response Third line: 0/2 achieved complete response, 2/2 achieved partial response Fifth line: 0/1 achieved complete response, 1/1 achieved partial response	 5.Yes 6.Yes 6.Yes 7.Yes 8.No 9.Yes 10.No Other comments: The study is a case series and, as such, is rated as poor in the hierarchy of study designs. However, there are few eligible participants for studies using new treatments in rare diseases (such as scleromyxedema), meaning it is difficult to conduct high quality studies. Key limitations are that the study was retrospective, treatment with
	 Baseline characteristics (reported for the entire cohort [n=30] and include people not on IV immunoglobulin alone, outcomes for these people are not reported in this review): 17 males and 13 females Mean age 59 years (range 34 to 86) 			IV immunoglobulin was open label, there was no comparator, and the sample size was small. As with many case series, the study was not powered for statistical hypothesis testing and the data should be regarded as descriptive only. Case series have no comparators, and unknown or unmeasured factors may have influenced the findings reported. Case series

Mean duration of scleromyxedema at diagnosis	cannot prove cause and be considered hypothesis	
9 months (range 1 to 60)	Source of funding: None	

Abbreviations

HAQ-DI, health assessment questionnaire disability index; IV, intravenous; MMRSS, modification of the modified Rodnan skin score; mRSSS, modified Rodnan skin score for scleromyxedema; PGA, physician global assessment; SD, standard deviation

Appendix F Quality appraisal checklists

Joanna Briggs Institute Critical Appraisal Checklist for Case Series

- 1. Were there clear criteria for inclusion in the case series?
- 2. Was the condition measured in a standard, reliable way for all participants included in the case series
- 3. Were valid methods used for the identification of the condition for all participants included in the case series?
- 4. Did the case series have consecutive inclusion of participants?
- 5. Did the case series have complete inclusion of participants?
- 6. Was there clear reporting of the demographics of the participants in the study?
- 7. Was there clear reporting of clinical information of the participants?
- 8. Were the outcomes or follow up results of cases clearly reported?
- 9. Was there clear reporting of the presenting site(s)/clinic(s) demographic information?
- 10. Was statistical analysis appropriate?

Appendix G GRADE profiles

Table 2: Question: In people with scleromyxedema, what is the clinical effectiveness and safety of human normal immunoglobulin as monotherapy or in addition to current standard care compared to standard care?

				Summary of findings				
	QUALITY			S	core	Effect		CERTAINTY
Risk of bias	Indirectness	Inconsistency	Imprecision	Pre IV immunoglob ulin treatment	Post IV immunoglobuli n treatment	Result	IMPORTANCE	
vity (4 case ser	ies)	•		•		·		
sponse, mean	33.5 months							
Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	First line: 3/6 Second line: 0/2 Third line: 0/2 Fifth line: 0/1	Critical	Very Low
sponse ^A , mean	44 months		-	L				
Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	-	-	2/8 (25%)	Critical	Very Low
sponse, mean	4.3 years	1		1	I	1		
Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	First line: 10/15 Second line: 2/6 Third line: 0/4	Critical	Very Low
nse, mean 33.	5 months		-					
Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	First line: 3/6 Second line: 2/2 Third line: 2/2 Fifth line: 1/1	Critical	Very Low
	vity (4 case ser sponse, mean 3 Very serious limitations ¹ sponse ^A , mean Serious limitations ³ very serious limitations ¹ Nery serious limitations ¹ very serious limitations ¹	vity (4 case series) sponse, mean 33.5 months Very serious limitations ¹ Serious indirectness ² sponse ^A , mean 44 months Serious limitations ³ Serious indirectness ² sponse, mean 4.3 years Very serious limitations ¹ Serious indirectness ² sponse, mean 4.3 years Very serious limitations ¹ Serious indirectness ² very serious limitations ¹ Serious indirectness ² very serious limitations ¹ Serious serious very serious Serious indirectness ²	Risk of biasIndirectnessInconsistencyrity (4 case series)sponse, mean 33.5 monthsVery serious limitations1Serious indirectness2Not applicablesponse^A, mean 44 monthsSerious limitations3Serious indirectness2Not applicablesponse, mean 44 monthsSerious limitations3Serious indirectness2Not applicablesponse, mean 4.3 yearsVery serious indirectness2Not applicableVery serious limitations1Serious indirectness2Not applicablesponse, mean 33.5 monthsVery serious SeriousNot applicable	Risk of biasIndirectnessInconsistencyImprecisionvity (4 case series)sponse, mean 33.5 monthsVery serious limitations1Serious indirectness2Not applicableNot calculablesponse^A, mean 44 monthsSerious limitations3Serious indirectness2Not applicableNot calculablesponse, mean 4.3 yearsVery serious indirectness2Not applicableNot calculablevery serious limitations1Serious indirectness2Not applicableNot calculablesponse, mean 4.3 yearsVery serious indirectness2Not applicableNot calculablevery serious limitations1Serious indirectness2Not applicableNot calculablevery serious limitations1Serious indirectness2Not applicableNot calculablevery serious limitations1Serious indirectness2Not applicableNot calculablevery serious limitations1Serious indirectness2Not applicableNot calculable	Risk of bias Indirectness Inconsistency Imprecision Pre IV immunoglob ulin treatment vity (4 case series) sponse, mean 33.5 months - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - sponse ^A , mean 44 months Serious indirectness ² Not applicable Not calculable - sponse, mean 4.3 years Very serious indirectness ² Not applicable Not calculable - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - sponse, mean 4.3 years Imprecision Not calculable - - very serious Serious indirectness ² Not applicable Not calculable -	QUALITY Score Risk of bias Indirectness Inconsistency Imprecision Pre IV immunoglobuli treatment Post IV immunoglobuli n treatment vity (4 case series) sponse, mean 33.5 months - - - Very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - - sponse, mean 44 months - - - - - sponse, mean 4.3 years Not applicable Not calculable - - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - sponse, mean 4.3 years Very serious indirectness ² Not applicable Not calculable - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - very serious limitations ¹ Serious indirectness ² Not applicable Not calculable -	CUALITY Score Effect Risk of bias Indirectness Inconsistency Imprecision Pre IV immunoglobuli treatment Post IV immunoglobuli n treatment Result vity (4 case series) series) series series <td< td=""><td>Score Effect Importance Risk of bias Indirectness Inconsistency Imprecision Pre IV immunoglobuli ntreatment Post IV immunoglobuli n treatment Result Importance sponse, mean 33.5 months - First line: 3/6 Second line: 0/2 Third line: 0/2 Critical Critical Very serious limitations¹ Serious indirectness² Not applicable Not calculable - First line: 0/2 Fifth line: 0/2 Critical sponse A, mean 44 months - Serious indirectness² Not applicable Not calculable - 2/8 (25%) Critical sponse, mean 4.3 years - Serious indirectness² Not applicable Not calculable - First line: 10/15 Second line: 2/6 Third line: 0/4 Critical very serious limitations¹ Serious indirectness² Not applicable Not calculable - First line: 10/15 Second line: 2/6 Third line: 0/4 Critical very serious limitations¹ Serious indirectness² Not applicable Not calculable - First line: 3/6 Second line: 2/2 Third line: 2/2 Critical</td></td<>	Score Effect Importance Risk of bias Indirectness Inconsistency Imprecision Pre IV immunoglobuli ntreatment Post IV immunoglobuli n treatment Result Importance sponse, mean 33.5 months - First line: 3/6 Second line: 0/2 Third line: 0/2 Critical Critical Very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - First line: 0/2 Fifth line: 0/2 Critical sponse A, mean 44 months - Serious indirectness ² Not applicable Not calculable - 2/8 (25%) Critical sponse, mean 4.3 years - Serious indirectness ² Not applicable Not calculable - First line: 10/15 Second line: 2/6 Third line: 0/4 Critical very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - First line: 10/15 Second line: 2/6 Third line: 0/4 Critical very serious limitations ¹ Serious indirectness ² Not applicable Not calculable - First line: 3/6 Second line: 2/2 Third line: 2/2 Critical

		QUALITY Summary of findings							
		QUALITY			S	core	Effect		CERTAINTY
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Pre IV immunoglob ulin treatment	Post IV immunoglobuli n treatment	Result	IMPORTANCE	
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	-	-	6/8 (75%)	Critical	Very Low
Partial respo	nse, mean 4.3	years							
Case series Mahevas et al. (2020)	Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	First line: 5/15 Second line: 4/6 Third line: 4/4	Critical	Very Low
mRSSS ^c , me	an 44 months ((Mean score, rar	nge 0 to 182; a low	er score indica	tes beneficial	result)			
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	82.38±40.76	14.88±12.99	p=0.012	Critical	Very low
MMRSS, 1 to	2 weeks after	IV immunoglobu	ılin (Mean score, r	ange 0 to 60; a	lower score in	dicates benefici	al result)		
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	13.6±2.6	10.3±1.9	p=0.003	Critical	Very low
Physician's g	lobal assessm	nent, mean 44 m	onths (measured o	on a scale of 0	to 2, where 0 =	no improvemen	t, 1= partial improvement, 2 = full in	nprovement)	
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable			5/8 scored 1 3/8 scored 2	Critical	Very low
Physicians g markedly wo		ent, 1 to 2 weeks	s after IV immunog	globulin (Mean;	; measured on	a scale of -4 to	+4, where +4 = markedly improved,	0 = no change, and	d −4 =
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	1.4±0.2	1.1±0.2	p=0.100	Critical	Very low
Body surface	area, 1 to 2 w	eeks after IV imr	nunoglobulin (Mea	an [%]; a lower	score indicate	es beneficial resu	llt)	1	1

						Summa			
QUALITY					Score		Effect	1	
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Pre IV immunoglob ulin treatment	Post IV immunoglobuli n treatment	Result	IMPORTANCE	CERTAINTY
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	36±38%	25±29%	p=0.099	Critical	Very low
Skin pain sco	ores, 1 to 2 wee	eks after IV immu	unoglobulin (Mear	; a lower score	e indicates ben	eficial result)		1	1
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	1.8±2.4	1.4±2.4	p=0.252	Critical	Very low
Skin scale fle	xibility scores	, 1 to 2 weeks af	ter IV immunoglob	bulin (Mean; ra	nge 0 to 10; a l	ower score indic	cates beneficial result)		1
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	5.4±3.5	3.3±3.1	p=0.013	Critical	Very low
Skin scale so	ftening scores	, 1 to 2 weeks at	ter IV immunoglo	bulin (Mean; ra	inge 0 to 10; a	lower score indi	cates beneficial result)		
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	4.9±3.4	2.7±2.5	p=0.022	Critical	Very low
Skin scale gl	obal, 1 to 2 we	eks after IV imm	unoglobulin (Mear	n; range 0 to 10); a lower score	e indicates bene	ficial result)	1	
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	4.5±3.3	2.7±2.4	p=0.029	Critical	Very low
Systemic inv	Systemic involvement/extracutaneous manifestations (1 case series)								
Systemic syn	nptoms, mean	44 months							
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable			All systemic symptoms improved with IV immunoglobulin except arthralgias in 2/8 participants	Critical	Very Low
Health related	Health related quality of life (1 case series)								
Health related	d quality of life	, 1 to 2 weeks af	ter IV immunoglol	oulin (Mean HAC	Q-DI; a lower sc	ore indicates be	neficial result)		

						Summary of findings			
QUALITY					Score		Effect		
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Pre IV immunoglob ulin treatment	Post IV immunoglobuli n treatment	Result	IMPORTANCE	CERTAINTY
Case series Mecoli et al (2020)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	0.62±0.7	0.54±0.2	p=0.403	Critical	Very low
Duration of c	linical improve	ement or respons	se to treatment (1	case series)					
Number of pe	eople who need	ded maintenance	e treatment with IV	/ immunoglobu	ılin, mean 44 m	nonths			
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable mmunoglobulin ti	Not calculable		-	6/8 (75%)	Important	Very Low
-	-	-	-	-				1	1
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	-	-	 2/8 (25%) who obtained complete response, stopped treatment after 7 and 11 months but relapses occurred after 6 and 25 months, respectively, and IV immunoglobulin was restarted 1/8 participant developed dermatoneuro syndrome after stopping IV immunoglobulin voluntarily; complete recovery of the neurological symptoms was seen after the reintroduction of IV immunoglobulin after one cycle in 3 weeks 	Important	Very Low
Progression t	o dermatoneu	ro syndrome (2 o	ase series)						
Progression t	o dermatoneu	ro syndrome, me	an 44 months						
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable	-	-	2/8 (25%)	Important	Very Low
Progression t	o dermatoneu	ro syndrome, cai	diac injury, or dea	nth, mean 21 m	onths (first line	e) and 24 month	s (second line)	<u> </u>	<u> </u>
Case series	Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	First line: 4/15	Important	Very Low

QUALITY						Summa	_		
					Score				Effect
Study	Risk of bias	Indirectness	Inconsistency	Imprecision	Pre IV immunoglob ulin treatment	Post IV immunoglobuli n treatment	Result	IMPORTANCE	CERTAINTY
Mahevas et al. (2020)							Second line: 1/6		
Safety (2 case	e series)			L				•	
Adverse even	its, mean 44 m	onths							
Case series Guarneri et al. (2017)	Serious limitations ³	Serious indirectness ²	Not applicable	Not calculable			13 adverse events in 5 people Adverse event (number of people): asthenia (4), headache (3), exfoliative keratolysis (2), acute hypertensive episodes (1), fever (1), dizziness (1), hypotension (1)	Important	Very Low
Severe side e	ffects, mean 21	months			I	I	I		
Case series Mahevas et al. (2020)	Very serious limitations ¹	Serious indirectness ²	Not applicable	Not calculable	-	-	1/15 people had thrombosis	Important	Very Low

Abbreviations

HAQ-DI, health assessment questionnaire disability index; IV, intravenous; mRSSS, modified Rodnan skin score; MMRSS, modification of the modified Rodnan Skin Score

A Where complete response was defined as no symptoms

B Where partial response was defined as a decrease in skin changes and improvement in systemic symptoms C Modified Rodnan skin score determined by these clinical features in 20 different body districts: skin thickening; papular involvement; erythema/dyspigmentation

1 Small numbers of participants were included in the study, retrospective study design with poor outcome reporting

2 Case series

3 Small numbers of participants were included in the study

Glossary

Arthralgias.	Discomfort, pain, or inflammation arising from any part of a joint including cartilage, bone, ligaments, tendons or muscles
Human normal immunoglobulin	Human normal immunoglobulin is used in a variety of conditions, many of which involve the immune system and reduce or stop antibody production. It is prepared using donated human plasma and contains immunoglobulin G (IgG) and antibodies to various viruses. It is generally given intravenously or subcutaneously.
Scleromyxedema	Scleromyxedema (scleromyxoedema) is an extremely rare condition involving pathological deposits of mucin in the skin and connective tissue.

References

Included studies

- Guarneri A, Cioni M, Rongioletti F (2017) High-dose intravenous immunoglobulin therapy for scleromyxedema: a prospective open-label clinical trial using an objective score for clinical evaluation system. JEADV 32, 1157-1160
- Mahevas T, Arnult B, Bouaziz JD et al. (2020) Plasma cell-directed therapies in monoclonal gammopathy-associated scleromyxedema. Blood;135(14) 1101-1110
- Mecoli CA., Talbot CC., Fava A et al. (2020) Clinical and molecular phenotyping in scleromyxedema pre- and post- treatment with intravenous immunoglobulin. Arthritis Care and Research, 72(6);761-767.

Rongioletti F, Merlo G, Cinotti E (2013) Scleromyxedema: a multicenter study of characteristics, comorbidities, course, and therapy in 30 patients. J Am Acad Dermatol, 69(1):66-72.

NHS England Wellington House 133-155 Waterloo Road London

SE1 8UG